桑 威 医学博士 副教授  主任医师  博士生导师

徐州医科大学附属医院血液科副主任，淋巴瘤病区主任，徐医附院细胞研究和转化医学中心副主任，中华医学会血液学分会淋巴瘤学组委员，中国抗癌协会淋巴瘤专委会委员，中国老年医学会淋巴瘤专委会委员，中国EBV相关疾病工作组秘书长，江苏省医学会血液学分会淋巴瘤学组副组长，江苏省抗淋巴瘤联盟副主席，徐州市抗癌协会生物和转化治疗专业委员会主任委员，徐州市免疫学会淋巴瘤专委会主任委员。

江苏省“六大人才高峰培养对象,江苏省“科教强卫工程"青年医学人才,江苏省333高层次人才培养对象。先后承担国家自然科学基金,中国博士后基金，江苏省自然科学基金,江苏省卫生厅,江苏省教育厅科研项目等科课题多项。

主要研究方向是淋巴瘤CART细胞治疗，EBV相关淋巴瘤的精准诊断和免疫治疗，CD5阳性淋巴瘤的诊断和治疗。近年来,先后在American Journal of Hematology, International journal of cancer,American journal of surgica.pathology ，Cancer，Celular immunology，Cancer medicine等杂志以第一或通讯作者发表科研论文50余篇,其中SCI收录30篇。

 

1. 输注全人源抗CD38 CAR-T治疗CD38阳性难治复发恶性血液肿瘤的安全性和有效性的单中心、开放、单臂临床研究，注册号ChiCTR2000033970

2. 同时靶向 LMP1 和 GP350 的双靶标嵌合抗原受体及其应用

 

1. 研究生多人次获得国家奖学金和学业一等奖学金

2. 指导2024年入学学术研究生两名（第一导师），专硕研究生两名（第一导师）

3. 指导2023年入学学术研究生两名（第一导师），专硕研究生两名（第一导师）

4. 指导2022年入学学术研究生一名（第一导师），专硕研究生三名（第一导师）

5. 指导2021年入学学术研究生一名（第一导师），专硕研究生三名（第一导师）

6. 指导2020年入学学术研究生一名（第一导师），专硕研究生三名（第一导师）

7. 指导2019年入学专硕研究生一名（第一导师）

 

1.江苏省科技厅社会发展重点研发项目，BE2019638，人源化抗LMP1和CD30特异双靶CAR-T细胞治疗EBV相关的复发难治性CD30阳性淋巴瘤的研究，2019.7-2022.6，200万，在研，主持

2.江苏省自然科学基金，BK20171181，CD5协同MiR-150自反馈调控IL-10/JAK2/STAT3信号通路在套细胞淋巴瘤发病中的作用，2017.7-2020.6,10万，在研，主持

3.江苏省博士后基金，1701134C，CD5协同miR-150分子在套细胞淋巴瘤发病中的作用机制研究，2017.7-2018.6，2万，在研，主持

4.“科教强卫工程”青年医学人才，QNRC2016791，CD5调控IL-10/JAK2/STAT3信号在MCL发病中的作用研究，2016.01-2020.12，25万，在研，主持

5.中国博士后基金，2016M601891，CD5调控IL-10/JAK2/STAT3信号在MCL发病中的作用研究，2016.01-2018.12，5万元，在研，主持

6.国家自然科学基金应急管理项目，08144110，MiR-181a靶向CARD11调控Th17细胞分化及其在aGVHD发生中的作用及机制研究，2015.01-2015.12，10万元，已结题，主持

7.江苏省高校自然科学基金，14KJB320024，MiR-181在T细胞分化及GVHD发生中的作用研究，2014.08-2016.12，3万元，已结题，主持

8.江苏省“六大人才高峰”项目，2012-WSW-035，microRNA表达谱在移植物抗宿主病发生及预测中的研究，2013.01-2015.12，3万元，已结题，主持

   

 

1.本科生内科学，诊断学

2.留学生淋巴瘤和诊断学课程

 

1.  Shen Z, Zhang S, Zhang M, Hu L, Sun Q, He C, Yan D, Ye J, Zhang H, Wang L, Gu W, Miao Y, Liu Q, Ouyang C, Zhu J, Wang C, Zhu T, Huang S, Sang W (corresponding author). The Addition of Ferritin Enhanced the Prognostic Value of International Prognostic Index in Diffuse Large B-Cell Lymphoma. Front Oncol. 2022 Jan 19;11:823079. doi: 10.3389/fonc.2021.823079. PMID: 35127536; PMCID: PMC8807645.

2.  Shen Z, Hu L, Yao M, He C, Liu Q, Wang F, Gu W, Wang Y, Dong M, Zhu T, Yin T, Li F, Jin Y, Huang S, Zhang H, Sang W (corresponding author); Huaihai Lymphoma Working Group (HHLWG). Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group. Int J Cancer. 2022 Jan 15;150(2):327-334. doi: 10.1002/ijc.33802. Epub 2021 Sep 24. PMID: 34520566.

3. Chen W, Ma Y, Shen Z, Chen H, Ma R, Yan D, Shi M, Wang X, Song X, Sun C, Cao J, Cheng H, Zhu F, Sun H, Li D, Li Z, Zheng J, Xu K, Sang W (corresponding author). Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. Front Immunol. 2021 Oct 29;12:755549. doi: 10.3389/fimmu.2021.755549. PMID: 34777367; PMCID: PMC8586453.

4. Shen Z, Wang F, He C, Li D, Nie S, Bian Z, Yao M, Xue Y, Wang Y, Gu W, Zhu T, Shi Y, Zhang H, Huang S, Miao Y, Sang W (corresponding author); Huaihai Lymphoma Working Group. The Value of Prognostic Nutritional Index (PNI) on Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: A Multicenter Retrospective Study of HHLWG Based on Propensity Score Matched Analysis. J Inflamm Res. 2021 Oct 27;14:5513-5522. doi: 10.2147/JIR.S340822. PMID: 34737600; PMCID: PMC8558829.

5.  Zhang S, Shen Z, He C, Hu L, Sun Q, Yan D, Jin Y, Huang S, Xu K, Sang W (corresponding author). Prognostic Values of GNRI, PNI, And CONUT in Patients with Diffuse Large B‐Cell Lymphoma.Annals of Case Reports & Reviews. doi: 10.39127/2574-5747/ACRR:1000282

6.  Shen Z, Wang L, Zhang B, Li T, Li D, He C, Xue Y, Wang Y, Li B, Liu Q, Zhang H, Gu W, Wang F, Wang C, Shi Y, Ye J, Zhu T, Miao Y, Huang S, Sang W (corresponding author). Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China. Front Oncol. 2021 Nov 3;11:754180. doi: 10.3389/fonc.2021.754180. PMID: 34804942; PMCID: PMC8595286.

7. Yan D, Shen Z, Zhang S, Hu L, Sun Q, Xu K, Jin Y, Sang W (corresponding author). Prognostic values of geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI) in elderly patients with Diffuse Large B-Cell Lymphoma. J Cancer. 2021 Oct 11;12(23):7010-7017. doi: 10.7150/jca.62340. PMID: 34729103; PMCID: PMC8558670.

8. Sang W (first author), Zhou H, Qin Y, Shen Z, Yan D, Sun C, Song X, Ma Y, Tu D, Bian Z, Nie S, Jin Y, Xu L, Li Z, Xu K. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era. Int J Hematol. 2021 Aug;114(2):189-198. doi: 10.1007/s12185-021-03145-3. Epub 2021 Apr 24. PMID: 33893987.

9. Sang W (first author), Shi M, Yang J, Cao J, Xu L, Yan D, Yao M, Liu H, Li W, Zhang B, Sun K, Song X, Sun C, Jiao J, Qin Y, Sang T, Ma Y, Wu M, Gao X, Cheng H, Yan Z, Li D, Sun H, Zhu F, Wang Y, Zeng L, Li Z, Zheng J, Xu K. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1. PMID: 32608579; PMCID: PMC7433814.

10. Zhang S, Sun C, Chen X, Li D, Hu L, Zhang M, Zhang X, Zhang H, Ye J, Wang L, Jia T, Zhu T, Miao Y, Wang C, Wang L, Yan D, Shen Z, Sang W (corresponding author). The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients. Ann Hematol. 2023 Jun;102(6):1433-1442. doi: 10.1007/s00277-023-05232-3. Epub 2023 Apr 19. PMID: 37074377.

11.  Sang W (first author), Wang X, Geng H, Li T, Li D, Zhang B, Zhou Y, Song X, Sun C, Yan D, Li D, Li Z, Li C, Xu K. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma. Front Immunol. 2022 Apr 1;13:858021. doi: 10.3389/fimmu.2022.858021. PMID: 35432352; PMCID: PMC9010867.

12. Sang W (first author), Tu D, Zhang M, Qin Y, Yin W, Song X, Sun C, Yan D, Wang X, Zeng L, Li Z, Xu K, Xu L. l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma. J Biochem Mol Toxicol. 2022 Aug;36(8):e23117. doi: 10.1002/jbt.23117. Epub 2022 Jun 27. PMID: 35757978.

13. Sang W (first author), Ma Y, Wang X, Ma Y, Shen Z, Gu W, Wang F, Ye J, Zhang C, Miao Y, Xu C, Liu Q, Li B, Tu J, Wang C, Shi Y, Sun S, Yan D, Song X, Sun C, Shao Y, Xu L, Li Z, Ma D, Xu K, Young KH, Liu H. Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study. Am J Surg Pathol. 2022 Nov 1;46(11):1533-1544. doi: 10.1097/PAS.0000000000001957. Epub 2022 Aug 26. PMID: 36006771.

14. Ma S, Zhang B, Lu T, Li D, Li T, Shen Z, He C, Wang Y, Li B, Zhang H, Gu W, Wang C, Ye J, Zhu T, Miao Y, Wang L, Huang S, Liu Q, Sang W (corresponding author); Huaihai Lymphoma Working Group. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group. Cancer. 2022 Oct 1;128(19):3487-3494. doi: 10.1002/cncr.34405. Epub 2022 Aug 6. PMID: 35932292.

15.Shen Z, Zhang S, Chen X, Zhang Q, Jiao Y, Shi Y, Zhang H, Ye J, Wang L, Zhu T, Miao Y, Wang L, Cai G, Sang W (corresponding author). Prognostic value of prognostic nutritional index on extranodal natural killer/T-cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working Group. Hematol Oncol. 2023 Jan 21. doi: 10.1002/hon.3124. Epub ahead of print. PMID: 36680513.

16. Shen, Z., Chen, X., Sun, C., Lu, T., Shi, Y., Zhang, H., ... & Sang W (corresponding author). Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T‐cell lymphoma. Cancer Medicine.

17. Shen, Z., Tan, Z., Ge, L., Wang, Y., Xing, X., Sang, W.(corresponding author), & Cai, G. (2024). The global burden of lymphoma: estimates from the Global Burden of Disease 2019 study. Public Health, 226, 199-206.

18. Wang, X., Zhou, Y., Sun, Q., Zhou, H., Zhang, Q., Shen, Z., ... & Sang, W(corresponding author).. (2023). Disparity Analysis of Clinical Features and Prognostic Evaluation of Hemophagocytic Lymphohistiocytosis in Pediatric and Adult Patients: A Retrospective Multicenter Study of 525 Cases in HHLWG. Acta Haematologica, 146(3), 185-195.

19. Zhang, S., Sun, C., Chen, X., Li, D., Hu, L., Zhang, M., ... & Sang, W(corresponding author).. (2023). The prognostic value of controlling nutritional status (CONUT) score–based nomogram on extranodal natural killer/T cell lymphoma patients. Annals of Hematology, 1-10.

20. Wang, X., Zhou, Y., Sun, Q., Zhang, Q., Zhou, H., Zhang, J., ... & Sang, W(corresponding author).. (2023). Thymosin β4 Exerts a Cytoprotective Function and Attenuates Liver Injury in Murine Hepatic Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy.

21. Xu, L., Zhang, M., Tu, D., Lu, Z., Lu, T., Ma, D., ... & Sang, W(corresponding author).. (2023). Chidamide induces EBV lytic infection and acts synergistically with tenofovir eliminate EBV-positive Burkitt lymphoma. Journal of Pharmacology and Experimental Therapeutics.

22. 张硕,沈子园,金英良, 桑威 （通讯作者）. 弥漫大B细胞淋巴瘤患者预后营养指数及临床特征与预后的关系[J]. 白血病·淋巴瘤,2021(10). DOI:10.3760/cma.j.cn115356-20210330-00063.

23.张硕,沈子园,桑威 （通讯作者）,淮海淋巴瘤协作组.老年营养风险指数在结外NK/T细胞淋巴瘤中的预后价值评估：一项淮海淋巴瘤工作组的多中心回顾性研究[J].临床血液学杂志,2022,35(09):633-638.DOI:10.13201/j.issn.1004-2806.2022.09.006.

24.孙倩,沈子园, 桑威 （通讯作者）.104例成人噬血细胞综合征的病因及临床特征对预后的影响分析[J].安徽医科大学学报,2022,57(08):1313-1317.DOI:10.19405/j.cnki.issn1000-1492.2022.08.026.

25.沈子园,康海全,金英良, 桑威 （通讯作者）. 血液科住院患者感染细菌分布及耐药情况分析[J]. 白血病·淋巴瘤,2022(1). DOI:10.3760/cma.j.cn115356-20200924-00236.

26.沈子园,贺晨露,孙倩, 桑威 （通讯作者）. 124例成人噬血细胞综合征临床预后分析：一项淮海淋巴瘤协作组多中心回顾性研究[J]. 中华血液学杂志,2021(10). DOI:10.3760/cma.j.issn.0253-2727.2021.10.002.

27.沈子园,陈玺丞,单慧蓉, 桑威 （通讯作者）. 培门冬酶/左旋门冬酰胺酶治疗结外NK/T细胞淋巴瘤的预后因素分析：多中心回顾性研究[J]. 中华血液学杂志,2023,44(8):642-648. DOI:10.3760/cma.j.issn.0253-2727.2023.08.005.

28.沈子园,胡灵灵,张颢, 桑威 （通讯作者）. EB病毒在结外NK/T细胞淋巴瘤中的预后价值:一项淮海淋巴瘤协作组的多中心回顾性研究[J]. 中国现代医学杂志,2023,33(21):9-15. DOI:10.3969/j.issn.1005-8982.2023.21.002.